Recent Company News

• 09:20 AM ET Apr 01, 2025
  

  StreetAccount Summary - US Pre-market trading update

• 09:02 AM ET Apr 01, 2025
  

  Connect Biopharma announces results from type C meeting with the FDA for Rademikibart ($0.55, 0.00)

• 04:10 PM ET Mar 31, 2025
  

  Connect Biopharma announces publication of data from global phase 2 trial of rademikibart in moderate-to-severe uncontrolled asthma ($0.55, 0.00)

• 09:03 AM ET Mar 31, 2025
  

  Connect Biopharma Holdings reports FY net income ($0.3M) vs year-ago ($1.1M) ($0.68, 0.00)

• 05:06 PM ET Sep 06, 2024
  

  Connect Biopharma Holdings CFO Steven Chan to step down effective 13-Sep-24 - 6-K ($1.25, 0.00)

• 04:21 PM ET Sep 05, 2024
  

  Connect Biopharma Holdings reports H1 net income $7.6M vs year-ago ($30.5M) ($1.20, 0.00)

• 04:18 PM ET Jun 12, 2024
  

  Connect Biopharma announces new leadership and chair of the board ($1.77, 0.00)

• 04:14 PM ET May 22, 2024
  

  Connect Biopharma presented late breaking poster presentation on the positive results from the rademikibart global Phase 2B trial in patients with moderate-to-severe asthma at the American Thoracic Society 2024 International Conference ($1.67, 0.00)